{"filing":{"accession_number":"0001193125-26-298526","cik":"0001653087","ticker":"ALEC","company_name":"Alector, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"alec-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/alec-20260706.htm"},"events":[{"id":16685,"run_id":14915,"accession_number":"0001193125-26-298526","anchor_item_number":"1.02","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses termination of two material definitive agreements: (1) the GSK Collaboration and License Agreement for development of investigational monoclonal antibodies latozinemab and nivisnebart, effective January 2, 2027, following failed Phase 3 and Phase 2 clinical trials; and (2) the Loan and Security Agreement with Hercules Capital, which the Company repaid in full ($10.4M principal plus interest and charges) on July 8, 2026. The GSK termination represents a material change in the Company's pipeline and strategic partnership following clinical trial failures, while the loan repayment signals a significant capital event. While Item 1.02 covers termination of material agreements, the substance here—loss of a major collaboration and debt restructuring—most closely aligns with material M\u0026A/strategic activity, though `financial_other` (debt repayment) or `operational_other` (partnership termination) could also apply.","company_name":"Alector, Inc.","ticker":"ALEC","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14857,"accession_number":"0001193125-26-298526","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of two material definitive agreements: (1) the GSK Collaboration and License Agreement for development of investigational monoclonal antibodies latozinemab and nivisnebart, effective January 2, 2027, following failed Phase 3 and Phase 2 clinical trials; and (2) the Loan and Security Agreement with Hercules Capital, which the Company repaid in full ($10.4M principal plus interest and charges) on July 8, 2026. The GSK termination represents a material change in the Company's pipeline and strategic partnership following clinical trial failures, while the loan repayment signals a significant capital event. While Item 1.02 covers termination of material agreements, the substance here—loss of a major collaboration and debt restructuring—most closely aligns with material M\u0026A/strategic activity, though `financial_other` (debt repayment) or `operational_other` (partnership termination) could also apply.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:07:06.754938+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14857,"accession_number":"0001193125-26-298526","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of two material definitive agreements: (1) the GSK Collaboration and License Agreement for development of investigational monoclonal antibodies latozinemab and nivisnebart, effective January 2, 2027, following failed Phase 3 and Phase 2 clinical trials; and (2) the Loan and Security Agreement with Hercules Capital, which the Company repaid in full ($10.4M principal plus interest and charges) on July 8, 2026. The GSK termination represents a material change in the Company's pipeline and strategic partnership following clinical trial failures, while the loan repayment signals a significant capital event. While Item 1.02 covers termination of material agreements, the substance here—loss of a major collaboration and debt restructuring—most closely aligns with material M\u0026A/strategic activity, though `financial_other` (debt repayment) or `operational_other` (partnership termination) could also apply.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:07:06.754938+00:00","company_name":"Alector, Inc.","ticker":"ALEC","filing_date":"2026-07-08"}]}